AAPG Ascentage Pharma Group Internat
14.94USD-7.15%Mkt Cap: 1.40B $P/E: —1d ago
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product can…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap1.40B USD
Enterprise Value1.71B USD
Revenue (TTM)642.64M USD
Gross Profit525.18M USD
Net Income (TTM)-1.24B USD
Revenue/Share6.91 USD
Last Price14.94 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees828
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.52
PEG—
EV/EBITDA-1.28
EV/Revenue2.66
P/S2.34
P/B18.09
EPS (TTM)-2.44
EPS (Forward)-1.04
52W Range
14.542% of range40.23
52W High40.23 USD
52W Low14.54 USD
Profitability
Gross Margin91.48%
Oper. Margin-248.91%
EBITDA Margin-207.87%
Profit Margin-216.47%
ROE-93.83%
ROA-31.35%
Growth
Revenue Growth29.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.17B USD
CapEx (TTM)27.57M USD
FCF Margin-148.85%
FCF Yield-68.56%
Net Debt198.99M USD
Net Debt/EBITDA-0.15
Balance Sheet
Debt/Equity1.49
Current Ratio1.22
Quick Ratio1.09
Book Value/Sh0.89 USD
Cash/Share20.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.13 USD
Upside (mean)+215.4%
Target Range40.00 USD – 55.00 USD
40.00+215.4% to mean55.00
# Analysts8
Ownership
Shares Out.93.39M
Float71.54M
Insiders0.00%
Institutions0.04%
Short Interest
Short Ratio2.6d
Short % Float0.03%
Short % Out.0.02%
Shares Short19.86K
Short (prev mo.)14.18K
Technical
SMA 5016.98 (-12.0%)
SMA 20021.32 (-29.9%)
Beta0.66
S&P 52W Chg16.45%
Avg Vol (30d)6.74K
Avg Vol (10d)5.94K
Technical Indicators
RSI (14)43.0
MACD-0.4650
MACD Signal-0.5188
MACD Hist.+0.0537
BB Upper16.75 USD
BB Middle15.59 USD
BB Lower14.44 USD
BB Width14.78%
ATR (14)0.7937 USD
Vol Ratio (20d)1.21x